Shanghai Cell Therapy Group Co., Ltd.
🇭🇰Hong Kong, China
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Holding, Subsidiary
- Established
- 2013-11-29
- Employees
- 1.1K
- Market Cap
- -
- Website
- http://www.shcell.com
Clinical Trials
16
Active:0
Completed:0
Trial Phases
3 Phases
Early Phase 1:8
Phase 1:4
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Early Phase 1
8 (53.3%)Phase 1
4 (26.7%)Not Applicable
3 (20.0%)An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Not Applicable
Recruiting
- Conditions
- Idiopathic Inflammatory Myopathies(IIM)Immune Thrombocytopenia(ITP)Systemic Lupus Erythematosus(SLE)
- Interventions
- Biological: CD19/CD22/BCMA CAR-T cells(BZE2204)
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT07174843
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai Municipality, China
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT07146672
- Locations
- 🇨🇳
Shanghai Mengchao Tumor Hospital, Shanghai, China
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Early Phase 1
Recruiting
- Conditions
- RelapsedRefractoryMultiple Myeloma
- Interventions
- Drug: CD19/CD20/BCMA CAR-T
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT06732232
- Locations
- 🇨🇳
China, Shanghai Mengchao Cancer Hospital, Shanghai, China
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Early Phase 1
Recruiting
- Conditions
- Non-Hodgkin Lymphoma, B-cell
- Interventions
- Biological: CD19/CD20/BCMA CAR T cells
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06446128
- Locations
- 🇨🇳
Mengchao Cancer Hospital, Shanghai, Shanghai, China
An Exploratory Study by Fast CAR T Cells
Early Phase 1
Recruiting
- Conditions
- Solid Tumor
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06327997
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found